Ireland
--:--IST
Starting soon Not applicable

The Effects of Acute Nitrate and Caffeine Co-ingestion on Discipline-Specific Exercise Performance.

NCT07748416 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2026-10-01
Last updated
2026-08-07

Condition(s) studied

Athletic PerformanceDietary SupplementIron Status

Investigational drug(s) / intervention(s)

CaffeineDietary Nitrate (Beetroot Juice)Placebo (Maltodextrin Capsule)Placebo (Nitrate-Depleted Beetroot Juice)

Caffeine: Anhydrous caffeine administered orally in a hard gelatine capsule. To address the unique physiological profiles of the two cohorts, a highly specific, differentiated dosing protocol is implemented: Cohort A (adult functional fitness athletes) will receive a high-performance dose of 6 mg/kg body mass, while Cohort B (elite junior swimmers) will receive a safe, youth-adapted dose of 3 mg/kg body mass. In all experimental trials, the capsule is ingested exactly 60 minutes prior to the onset of the discipline-specific exercise test to match peak plasma caffeine concentration.

Dietary Nitrate (Beetroot Juice): Concentrated beetroot juice (BJ) administered as a single, acute organic shot of 70 mL (Beet It Sport, James White Drinks Ltd., Ipswich, UK). Each active shot contains approximately 400 mg (equivalent to \~6.4 mmol) of inorganic nitrate. In contrast to chronic loading designs, this study evaluates purely acute effects; the shot is ingested exactly 3 hours (180 minutes) prior to the physical performance test to align with peak systemic concentration of plasma nitrite.

Placebo (Maltodextrin Capsule): Placebo capsule containing inert maltodextrin powder. The capsule is identical in size, shape, weight, color (opaque), and texture to the active caffeine capsule to ensure robust blinding. It is administered at the exact same time point (60 minutes pre-exercise) according to the identical body-mass-adjusted dosing scheme (simulating either 3 mg/kg or 6 mg/kg).

Placebo (Nitrate-Depleted Beetroot Juice): Nitrate-depleted beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK) administered as a 70 mL shot. This placebo is identical in taste, smell, appearance, packaging, and viscosity to the active concentrated shot, but has been selectively filtered to contain negligible nitrate levels (\<0.4 mmol / \~25 mg of nitrates). It is ingested exactly 3 hours prior to the exercise test.

Study summary

The purpose of this study is to investigate the acute, separate, and combined ergogenic effects of dietary nitrate (beetroot juice, BJ) and caffeine (CAF) supplementation on discipline-specific athletic performance. The project employs a double-blind, randomized, placebo-controlled, four-arm crossover design. It evaluates two highly distinct, heterogeneous populations of athletes: (A) adult high-intensity functional training (HIFT/CrossFit/Hyrox) competitors performing the standardized Hyrox Physical Fitness Test (P'F'T), and (B) elite junior competitive swimmers (National Team members) performing a progressive 8 × 100 m swimming test. The study will assess physical performance, lactate kinetics, subjective exertion, biochemical indices, psychological metrics, and gastrointestinal tolerance.

Eligibility

Sex
ALL
Min age
16 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: A) Cohort A (HIFT / CrossFit / Hyrox): * Aged 18-45 years. * Minimum of 2 years of systematic HIFT/CrossFit/Hyrox training experience. * Performing \>4 training sessions per week. * Ability to perform the HYROX Physical Fitness Test (P'F'T) and has participated in at least one official HYROX event. * Possession of a valid medical certificate proving eligibility for competitive sports. B) Cohort B (Competitive Junior Swimmers): * Aged 16-19 years. * Active member of the Polish Junior National Swimming Team. * Minimum of 5 years of competitive swimming experience. * Current training volume of at least 8-10 pool training sessions per week. * Written informed consent obtained from both the participant and their legal guardian (for minors under 18). C)Common Criteria for Both Cohorts: * No history of cardiovascular, respiratory, metabolic, or musculoskeletal disease contradicting high-intensity exercise or stimulant intake. * No known food allergies or adverse reactions to beetroot products or caffeine. * No current use of medications that alter nitrate/caffeine metabolism (e.g., proton pump inhibitors, antibiotics, phosphodiesterase inhibitors). * History of uneventful habituation to caffeine use during training/competition. * Willingness to abstain from dietary supplements, antibacterial mouthwashes, alcohol, and high-nitrate foods for 48 hours prior to each testing session. * Good general health and physical well-being. Exclusion Criteria (Applicable to both cohorts): * Occurrence of acute musculoskeletal injury or trauma during the study period. * Any medical or health contraindications (including severe menstrual disorders, planned pregnancy, or breastfeeding). * Failure or refusal to strictly adhere to the dietary, supplementation, and exercise testing protocols.

Primary outcome measure(s)

  • Exercise Performance Time (minutes and seconds, Cohort A - Hyrox P'F'T) — At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).
    Total time (in minutes and seconds) required to complete the standardized HYROX Physical Fitness Test (P'F'T) consisting of 6 specific functional exercises.
  • Swimming Performance (minutes and seconds, Cohort B - 8x100m Step-Test) — At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).
    Swimming performance will be assessed using the completion time (seconds and milliseconds) for each 100-m repetition of the standardized 8 × 100-m step test, including the maximal-effort repetition performed during the fifth stage.

Trial sites (1)

FacilityCityRegionStatus
Poznan University of Physical Education Poznan Wielkopolska
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07748416 on ClinicalTrials.gov ↗ ← All trials in Poland